Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 298

The DOI matches its Crossref record; 123 of the 123 references it cites were found in a registry or an index.

Inhibition of the fibroblast growth factor receptor (FGFR) pathway: the current landscape and barriers to clinical application

Open access
Chae, Young Kwang, Ranganath, Keerthi, Hammerman, Peter S., Vaklavas, Christos, Mohindra, Nisha, Kalyan, Aparna, Matsangou, Maria, Costa, Ricardo, Carneiro, Benedito, Villaflor, Victoria M., Cristofanilli, Massimo, Giles, Francis J.·2017·Oncotarget

Abstract

// Young Kwang Chae 1,2,3,* , Keerthi Ranganath 3,* , Peter S. Hammerman 4 , Christos Vaklavas 5 , Nisha Mohindra 1,2,3 , Aparna Kalyan 1,2,3 , Maria Matsangou 1,2,3 , Ricardo Costa 1 , Benedito Carneiro 1,2,3 , Victoria M. Villaflor 1,2,3 , Massimo Cristofanilli 1,2,3 and Francis J. Giles 1,2,3 1 Developmental Therapeutics Program of the Division of Hematology Oncology, Chicago, IL, USA 2 Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL, USA 3 Northwestern University Feinberg School of Medicine, Chicago, IL, USA 4 Dana Farber Cancer Institute, Boston, MA, USA 5 Division of Hematology Oncology, University of Alabama Birmingham, Birmingham, AL, USA * These authors have contributted equally to this work Correspondence to: Young Kwang Chae, email: // Keywords : fibroblast growth factor receptor inhibition Received : September 24, 2016 Accepted : November 22, 2016 Published : December 22, 2016 Abstract The fibroblast growth factor/fibroblast growth factor receptor (FGF/FGFR) is a tyrosine kinase signaling pathway that has a fundamental role in many biologic processes including embryonic development, tissue regeneration, and angiogenesis. Increasing evidence indicates that this pathway plays a critical role in oncogenesis via gene amplification, activating mutations, or translocation in tumors of various histologies. With multiplex sequencing technology, the detection of FGFR aberrations has become more common and is tied to cancer cell proliferation, resistance to anticancer therapies, and neoangiogenesis. Inhibition of FGFR signaling appears promising in preclinical studies, suggesting a pathway of clinical interest in the development of targeted therapy. Phase I trials have demonstrated a manageable toxicity profile. Currently, there are multiple FGFR inhibitors under study with many non-selective (multi-kinase) inhibitors demonstrating limited clinical responses. As we progress from the first generation of non-selective drugs to the second generation of selective FGFR inhibitors, it is clear that FGFR aberrations do not behave uniformly across cancer types; thus, a deeper understanding of biomarker strategies is undoubtedly warranted. This review aims to consolidate data from recent clinical trials with a focus on selective FGFR inhibitors. As Phase II clinical trials emerge, concentration on patient selection as it pertains to predicting response to therapy, feasible methods for overcoming toxicity, and the likelihood of combination therapies should be utilized. We will also discuss qualities that may be desirable in future generations of FGFR inhibitors, with the hope that overcoming these current barriers will expedite the availability of this novel class of medications.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.18632/oncotarget.14109

Cites

123 of 123 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 123 references

Cited by

See all 298

Metadata

Authors
Chae, Y. K., Ranganath, K., Hammerman, P. S., Vaklavas, C., Mohindra, N., Kalyan, A., Matsangou, M., Costa, R., Carneiro, B., Villaflor, V. M., Cristofanilli, M., & Giles, F. J.
Venue
Oncotarget
Published
2016-12-22
Volume
8
Issue
9
Pages
16052-16074
ISSN
1949-2553 (ISSN-L)
OpenAlex
W2566505805
Cited by
298
References
123
FWCI
14.75
Type
journal article
Language
en
Open access
diamond

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Inhibition of the fibroblast growth factor receptor (FGFR) pathway: the current landscape and barriers to clinical application. https://app.cochat.ai/papers/10.18632/oncotarget.14109
The paper
Chae, Y. K., Ranganath, K., Hammerman, P. S., Vaklavas, C., Mohindra, N., Kalyan, A., Matsangou, M., Costa, R., Carneiro, B., Villaflor, V. M., Cristofanilli, M., & Giles, F. J. (2017). Inhibition of the fibroblast growth factor receptor (FGFR) pathway: the current landscape and barriers to clinical application. Oncotarget. https://doi.org/10.18632/oncotarget.14109

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.